

Peptide Array, Dengue Virus Type 3 (DEN-3), Philippines/H87/1956, NS1 Protein

Catalog No. NR-2753

This reagent is the tangible property of the U.S. Government.

For research use only. Not for human use.

Contributor:

NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH

Product Description:

The 60-peptide array spans the NS1 protein of Dengue virus type 3, Philippines/H87/1956 (GenPept: AAA99437).¹ Peptides are 13- to 17-mers, with 11 or 12 amino acid overlaps. Please see Table 1 for length and sequence of individual peptides.

Material Provided:

Peptides are provided lyophilized at 1 mg per vial.

Packaging/Storage:

Lyophilized peptides should be placed in a closed dry environment with dessicants and stored at -20°C or colder immediately upon arrival. A frost-free freezer should be avoided, since changes in moisture and temperature may affect peptide stability.

Solubility:

Solubility may vary based on the amino acid content of the individual peptide (see Table 2).

Reconstitution:

Lyophilized peptides should be warmed to room temperature for 1 hour prior to reconstitution. They should be dissolved at the highest possible concentration, and then diluted with water or buffer to the working concentration. Buffer should be added only after the peptide is completely in solution because salts may cause aggregation.

The most common dissolution process is 1 mg of peptide in 1 mL of sterile, distilled water. Peptides that are not soluble in water can almost always be dissolved in DMSO. Once a peptide is in solution, the DMSO can be slowly diluted with aqueous medium. Care must be taken to ensure that the peptide does not begin to precipitate out of solution. For cell-based assays, 0.5% DMSO in medium is usually well-tolerated.

Sonication and/or the addition of small amounts of dilute (10%) aqueous acetic acid for basic peptides, aqueous ammonia for acidic peptides or acetonitrile may also help dissolution (see Table 2). These solvents may not be

appropriate for certain applications, including cell-based assays.

Storage of Reconstituted Peptides:

The shelf life of peptides in solution is very limited, especially for sequences containing cysteine, methionine, tryptophan, asparagine, glutamine, and N-terminal glutamic acid. In general, peptides may be aliquoted and stored in solution for a few days at -20°C or colder. For long-term storage, peptides should be re-lyophilized and stored at -20°C or colder. If long-term storage in solution is unavoidable, peptide solutions should be buffered to pH 5–6, aliquoted and stored at -20°C or colder. Freeze-thaw cycles should be avoided.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Peptide Array, Dengue Virus Type 3 (DEN-3), Philippines/H87/1956, NS1 Protein, NR-2753."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI

Biodefense and Emerging Infections Research Resources Repository

P.O. Box 4137

Manassas, VA 20108-4137 USA

www.beiresources.org

E-mail: contact@beiresources.org

800-359-7370

Fax: 703-365-2898



Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale. This material may be subject to third party patent rights.

References:

- Osatomi, K. and H. Sumiyoshi. "Complete Nucleotide Sequence of Dengue Type 3 Virus Genome RNA." <u>Virology</u> 176 (1990): 643–647. PubMed: 2345967.
- Modis, Y., et al. "Variable Surface Epitopes in the Crystal Structure of Dengue Virus Type 3 Envelope Glycoprotein." <u>J. Virol.</u> 79 (2005): 1223–1231. PubMed: 15613349.

ATCC[®] is a trademark of the American Type Culture Collection.

Table 1			
Peptide	Length	Sequence	
1 of 60	16	1 DMGCVINWKGKELKCG 16	
2 of 60	17	6 INWKGKELKCGSGIFVT 22	
3 of 60	17	11 KELKCGSGIFVTNEVHT 27	
4 of 60	17	17 SGIFVTNEVHTWTEQYK 33	
5 of 60	15	23 NEVHTWTEQYKFQAD 37	
6 of 60	17	27 TWTEQYKFQADSPKRVA 43	
7 of 60	17	33 KFQADSPKRVATAIAGA 49	
8 of 60	16	39 PKRVATAIAGAWENGV 54	
9 of 60	17	44 TAIAGAWENGVCGIRST 60	
10 of 60	17	50 WENGVCGIRSTTRMENL 66	
11 of 60	17	56 GIRSTTRMENLLWKQIA 72	
12 of 60	17	62 RMENLLWKQIANELNYI 78	
13 of 60	17	68 WKQIANELNYILWENDI 84	
14 of 60	17	73 NELNYILWENDIKLTVV 89	
15 of 60	17	79 LWENDIKLTVVVGDITG 95	
16 of 60	17	85 KLTVVVGDITGVLEQGK 101	
17 of 60	17	91 GDITGVLEQGKRTLTPQ 107	
18 of 60	17	97 LEQGKRTLTPQPMELKY 113	
19 of 60	17	103 TLTPQPMELKYSWKTWG 119	
20 of 60	17	109 MELKYSWKTWGLAKIVT 125	
21 of 60	16	115 WKTWGLAKIVTAETQN 130	
22 of 60	17	120 LAKIVTAETQNSSFIID 136	
23 of 60	17	126 AETQNSSFIIDGPSTPE 142	
24 of 60	17	132 SFIIDGPSTPECPSASR 148	
25 of 60	17	138 PSTPECPSASRAWNVWE 154	
26 of 60	17	144 PSASRAWNVWEVEDYGF 160	
27 of 60	17	150 WNVWEVEDYGFGVFTTN 166	
28 of 60	17	155 VEDYGFGVFTTNIWLKL 171	
29 of 60	17	161 GVFTTNIWLKLREVYTQ 177	
30 of 60	17	167 IWLKLREVYTQLCDHRL 183	

800-359-7370

NR-2753_02JUL2007



Table 1		
Peptide	Length	Sequence
31 of 60	17	172 REVYTQLCDHRLMSAAV 188
32 of 60	17	178 LCDHRLMSAAVKDERAV 194
33 of 60	17	184 MSAAVKDERAVHADMGY 200
34 of 60	17	190 DERAVHADMGYWIESQK 206
35 of 60	17	196 ADMGYWIESQKNGSWKL 212
36 of 60	17	202 IESQKNGSWKLEKASLI 218
37 of 60	17	208 GSWKLEKASLIEVKTCT 224
38 of 60	17	214 KASLIEVKTCTWPKSHT 230
39 of 60	17	220 VKTCTWPKSHTLWSNGV 236
40 of 60	17	226 PKSHTLWSNGVLESDMI 242
41 of 60	17	232 WSNGVLESDMIIPKSLA 248
42 of 60	17	237 LESDMIIPKSLAGPISQ 253
43 of 60	17	243 IPKSLAGPISQHNHRPG 259
44 of 60	17	249 GPISQHNHRPGYHTQTA 265
45 of 60	17	255 NHRPGYHTQTAGPWHLG 271
46 of 60	17	261 HTQTAGPWHLGKLELDF 277
47 of 60	17	267 PWHLGKLELDFNYCEGT 283
48 of 60	17	273 LELDFNYCEGTTVVISE 289
49 of 60	17	279 YCEGTTVVISENCGTRG 295
50 of 60	17	285 VVISENCGTRGPSLRTT 301
51 of 60	17	291 CGTRGPSLRTTTVSGKL 307
52 of 60	15	297 SLRTTTVSGKLIHEW 311
53 of 60	17	301 TTVSGKLIHEWCCRSCT 317
54 of 60	17	307 LIHEWCCRSCTLPPLRY 323
55 of 60	16	313 CRSCTLPPLRYMGEDG 328
56 of 60	17	318 LPPLRYMGEDGCWYGME 334
57 of 60	17	324 MGEDGCWYGMEIRPINE 340
58 of 60	17	330 WYGMEIRPINEKEENMV 346
59 of 60	17	336 RPINEKEENMVKSLASA 352
60 of 60	13	341 KEENMVKSLASAG 353

Table 2				
Peptide	Solubility	Solvent		
1 of 60	1 mg/mL	0.05% trifluoroacetic acid in water		
2 of 60	1 mg/mL	0.05% trifluoroacetic acid in water		
3 of 60	1 mg/mL	0.05% trifluoroacetic acid in water		
4 of 60	1 mg/mL	0.05% trifluoroacetic acid in water		
5 of 60	1 mg/mL	0.05% trifluoroacetic acid in water		
6 of 60	1 mg/mL	0.05% trifluoroacetic acid in water		

Page 3 of 5

Biodefense and Emerging Infections Research Resources Repository

P.O. Box 4137

Manassas, VA 20108-4137 USA

www.beiresources.org

© 2007 American Type Culture Collection (ATCC). All rights reserved.

800-359-7370

NR-2753_02JUL2007



	Table 2				
Peptide	Solubility	Solvent			
7 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
8 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
9 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
10 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
11 of 60	1 mg/mL	70% acetonitrile and 0.05% trifluroacetic acid in water			
12 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
13 of 60	1 mg/mL	100% DMSO			
14 of 60	1 mg/mL	100% DMSO			
15 of 60	1 mg/mL	100% DMSO			
16 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
17 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
18 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
19 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
20 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
21 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
22 of 60	1 mg/mL	70% acetonitrile and 0.05% trifluroacetic acid in water			
23 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
24 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
25 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
26 of 60	1 mg/mL	70% acetonitrile and 0.05% trifluroacetic acid in water			
27 of 60		100% DMSO			
28 of 60	1 mg/mL 1 mg/mL	70% acetonitrile and 0.05% trifluroacetic acid in wate			
29 of 60		0.05% trifluoroacetic acid in water			
30 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
31 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
	1 mg/mL				
32 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
33 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
34 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
35 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
36 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
37 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
38 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
39 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
40 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
41 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
42 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
43 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
44 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
45 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
46 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
47 of 60	1 mg/mL	100% DMSO			
48 of 60	1 mg/mL	100% DMSO			

800-359-7370

Fax: 703-365-2898



	Table 2				
Peptide	Solubility	Solvent			
49 of 60	1 mg/mL	100% DMSO			
50 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
51 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
52 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
53 of 60	1 mg/mL	70% acetonitrile and 0.05% trifluroacetic acid in water			
54 of 60	1 mg/mL	70% acetonitrile and 0.05% trifluroacetic acid in water			
55 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
56 of 60	1 mg/mL	70% acetonitrile and 0.05% trifluroacetic acid in water			
57 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
58 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
59 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			
60 of 60	1 mg/mL	0.05% trifluoroacetic acid in water			

800-359-7370

Fax: 703-365-2898